Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.
暂无分享,去创建一个
Saibal Kar | Matthew J Price | M. Price | Jose M. Sanchez | V. Reddy | D. Holmes | S. Kar | H. Sievert | M. Valderrábano | Vivek Y Reddy | David R Holmes | Horst Sievert | Miguel Valderrabano | Shephal K Doshi | Jose M Sanchez | S. Doshi
[1] M. Price,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.
[2] C. Richards,et al. Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.
[3] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[4] D. Packer,et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.
[5] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[6] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.
[7] J. Piccini,et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. , 2012, Heart rhythm.
[8] Petr Neuzil,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.
[9] W. Baker,et al. Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation , 2012, Circulation. Cardiovascular quality and outcomes.
[10] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[11] D. Levy,et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.
[12] G. Wander,et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection In Patients With Atrial Fibrillation) trial. , 2013 .
[13] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[14] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[15] J. de Lemos,et al. Emergency hospitalizations for adverse drug events. , 2012, The New England journal of medicine.
[16] P. Wolf,et al. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.
[17] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[18] E. Tuzcu,et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. , 2014, JACC. Cardiovascular interventions.
[19] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[20] A. Camm,et al. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] G. Mead,et al. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. , 2011, Age and ageing.
[22] J. Halperin,et al. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. , 2012, European heart journal.
[23] J. Avorn,et al. Patients’ Preferences in Anticoagulant Therapy: Discrete Choice Experiment , 2014, Circulation. Cardiovascular quality and outcomes.
[24] Andrea Natale,et al. Percutaneous Closure of the Left Atrial Appendage. , 2012, Cardiac electrophysiology clinics.
[25] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[26] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[27] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[28] J. Halperin,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[29] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[31] A. Go. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. , 2005, The American journal of geriatric cardiology.
[32] G. Lip,et al. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.
[33] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[34] Saibal Kar,et al. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.